2-Methyl-2-phenoxypropanoic acid (fibric acid) derivatives are called fibrates [1] [2] [3] and clinically useful in hyperlipidemic patients who show from middle to high levels of triglyceridemia. Although clofibrate, 4) one of the first generation fibrates, has been frequently used until quite recently, the second generation fibrates such as bezafibrate, [5] [6] [7] [8] fenofibrate, [9] [10] [11] [12] [13] [14] [15] [16] and gemfibrozil 4, 17) have been developed and are now clinically used for the treatment of hyperlipidemia. Gemfibrozil having a 5-phenoxy-pentanoic acid moiety instead of the fibric acid moiety, is also called an exceptionally new fibrates because of having almost similar pharmacological activity as the other fibrates possessing fibric acid moieties.
New Strong Fibrates with Piperidine Moiety
Teruo KOMOTO,* , a Hiroyuki HIROTA, a Mari OTSUKA, a Jiro KOTAKE, a Susumu HASEGAWA, commercially available 1-(3-methoxyphenyl)piperazine as shown in Chart 5. The N-benzoylpiperazine derivative (13) prepared by the acylation of 1-(3-methoxyphenyl)piperazine with 4-fluorobenzoyl chloride was demethylated using ethanethiol and aluminum chloride to give the phenol (14) which was reacted with ethyl 2-bromo-2-methylpropanoate followed by alkaline hydrolysis to yield the 2-phenoxypropanoic acid (15) . Pharmacological Activity The pharmacological activity of 4b having the phenoxyacetic acid moiety of 4a replaced with the 2-phenoxy-2-methylpropanoic acid moiety, which is common to fibrate-type compounds, was evaluated. The potency of reducing cholesterol and b-lipoprotein (b-LP) in serum did not change when compared with 4a. Compound 4c, having the sulfonyl group replaced with the benzoyl group, showed almost equipotent activity to 4b. Compound 4d, having the chlorine group of the phenyl ring of 4c replaced with the fluorine group, showed a stronger total cholesterol (T-CHOL)-and b-LP-lowering effect than 4a-c or bezafibrate.
Among the compounds (4d, 9aA, 12, 15) having a 4-hydroxypiperidine, piperidine, piperidin-3-ene, or piperazine moiety, 9aA showed the strongest activity. When the substitution position of the 2-methylpropanoic acid moiety on the phenyl group was changed from meta to ortho or para, the meta-substituted compound (9aA) showed the strongest activity among the derivatives.
Although several compounds (9aB-9aM) had the 4-fluorobenzoyl group of 9aA replaced with other substituted benzoyl or 3-pyridinecarbonyl groups, 9aA showed the most potent activity in reducing the T-CHOL and b-LP in serum. As shown in Table 1 , compounds 9aL and 9aM were not tested in the high-cholesterol diet-fed mice, but they were estimated using normal mice and the results are shown in Table 2 . They showed the reducing potencies between those of 9aD (or 9aE) and 9aJ on b-LP and triglyceride (TG) in serum.
The pharmacological profiles of 9aA were studied in rats and mice. First, the reducing effects of 9aA on the serum TG and T-CHOL levels were estimated in high-cholesterol dietfed rats in comparison with bezafibrate (Table 3) . Second, the reducing effects of 9aA on the serum TG were estimated in fructose-induced hypertriglycemic rats and compared with bezafibrate, fenofibrate and gemfibrozil (Table 4 ). The reducing effects of 9aA on the serum glucose and TG were then estimated in KK-A y mice and compared with bezafibrate ( Table 5) . As a result, the reducing activity of 9aA on the TG and T-CHOL levels was greater than 10 times more potent than that of bezafibrate. The hypoglycemic effects of 9aA in KK-A y mice were also greater than 10 times more potent than those of bezafibrate. Now, Patients with NIDDM (non-insulin-dependent diabetes mellitus) commonly have dyslipiedaemia (especially hypertriglyceridaemia and low HDL (high density lipoprotein) cholesterol levels) and are at high risk of coronary heart disease. 8) In this paper, 9aA improved the lipid profile in several animal models, additionally this compound showed hypoglycemic effect in a spontaneous NIDDM mouse model. These results indicate that 9aA may be a useful therapeutic candidate for NIDDM patients with hyperlipidaemia.
As mentioned above, after evaluation of several pharmacological studies, it was clarified that 9aA possesses an additional hypoglycemic effect along with the strong reducing effect on serum cholesterol and TG. Detailed studies of the mechanism and action of 9aA will be reported separately. Mice (nϭ6) were given high-cholesterol diet (1% cholesterol and 0.5% cholic acid) for 7 d. Drugs were orally administered on days 6 and 7. Each value represents the MED (minimum effective dose, reducing 15% in T-CHOL and 20% in b-LP, respectively). NT: Not tested. Since 2-[3-[1-(4-fluorobenzoyl)piperidin-4-yl]phenoxy]-2-methylpropanoic acid (9aA: AHL-157) was selected as a novel synthesized fibrate-type compound as described above, we examined the procedure for the large scale synthesis of 9aA. The transformation of 8a to 9aA was effectively achieved under the reaction conditions 18) using acetone, chloroform, and sodium hydroxide as shown in Chart 6.
Conclusion
Novel fibrates with 4-hydroxypiperidine, piperidine, piperidin-3-ene, and piperazine moieties in the center of the structure were synthesized. It was found that 1) 9aA with the piperidine moiety showed a strong total cholesterol-and b-LP-lowering effect in mice, 2) the reducing activity of 9aA on TG in rats and mice is greater than 10 times more potent than that of bezafibrate, and 3) the hypoglycemic effect of 9aA in KK-A y mice is also greater than 10 times more potent than that of bezafibrate. 9aA was finally selected as the most Chart 6 
Experimental
Melting points were determined on a Yanaco micro melting point apparatus without correction. IR spectra were measured with a Perkin-Elmer 1600 FT-IR spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-EX400 FT-NMR spectrometer in CDCl 3 or dimethyl sulfoxide (DMSO)-d 6 using tetramethylsilane as the internal reference. The following abbreviations were used: sϭsinglet, dϭdoublet, ddϭdouble doublet, dtϭdouble triplet, tϭtriplet, qϭquartet, mϭmultiplet and brϭbroad. FAB-MS, electron ionization mass spectrometry (EI-MS) or high-resolution mass spectrometry (HR-MS) were obtained using JEOL JMS-DX303 or JEOL JMS-AX500 mass spectrometer. TLC was performed by using Silica gel 60F 254 (Merck).
Column chromatography was performed with Silica gel 60 (70-230 mesh) Tables 6 and 7 .
1-Benzyl-4-[3-(benzyloxy)phenyl]-4-hydroxypiperidine (1)
A solution of 3-benzyloxy bromobenzene (13.0 g, 49.4 mmol) in tetrahydrofuran (THF) (50 ml) was dropwise added to a stirred mixture of Mg (1.21 g, 49.8 mmol) and I 2 (catalytic amount) in THF (30 ml) at 40°C over 30 min, and the mixture was stirred at reflux for 2 h. After cooling, a solution of 1-benzyl-4-piperidone (7.20 g, 37.7 mmol ) in THF (50 ml) was added dropwise to the stirred mixture at room temperature over a 30 min period, and then stirred at reflux for 2 h. After cooling, aq. sat. NH 4 Cl. (50 ml) was added dropwise, and the reaction mixture was extracted with Et 2 O. The organic layer was dried, concentrated in vacuo to give a pale brown oil which was purified by column chromatography on silica gel, eluting with 50% AcOEt in n-hexane to give 1 (10.3 g, 73%) , ethyl 2-bromo-2-methylpropanoate (0.1 mol) and K 2 CO 3 (30 mmol) was stirred at 100°C for 8 h. The mixture was poured into H 2 O and extracted with CHCl 3 , and the CHCl 3 layer was concentrated in vacuo. The residue was dissolved in a mixture of 1 N NaOH (50 ml), MeOH (50 ml), and 1,4-dioxane (50 ml), and then stirred for 1 h at room temperature. The mixture was poured into H 2 O, acidified with dil. HCl to pH 3, and extracted with CHCl 3 . The CHCl 3 layer was washed with H 2 O, dried, and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with 5% MeOH in CHCl 3 to give an oil which was crystallized from Et 2 O to give 4 as a white solid.
1-Benzyl-4-(methoxyphenyl)-1,2,3,6-tetrahydropyridine · HCl (5) (General Procedure C)
A solution of methoxybromobenzene (1.10 mol) in THF (350 ml) was added dropwise to a stirred mixture of Mg (1.10 mol) and I 2 (catalytic amount) in THF (100 ml) at 40°C over a 1 h period, then stirred at reflux for 1 h. After cooling, a solution of 1-benzyl-4-piperidinone (1.0 mol) in THF (250 ml) was added dropwise to the stirred mixture at room temperature over a 1 h period, and then stirred at reflux for 1 h. After cooling, sat. aq. NH 4 Cl (400 ml) and H 2 O (200 ml) were added to the mixture, then allowed to stand for a short time. The mixture was partitioned between THF and H 2 O, and the organic layer was washed with brine, then concentrated in vacuo. The residue was dissolved in a mixture of 1,4-dioxane (500 ml) and 6 N HCl (1000 ml), then refluxed for 3 h. After cooling, the mixture was concentrated in vacuo, and the residue was triturated with Et 2 O to give 5 as a white solid. : 2502. 4-(Hydroxyphenyl)piperidine (7) (General Procedure E) A mixture of 6 (500 mmol) and 47% hydrobromic acid (300 g, 1.74 mol) was refluxed with stirring for 2 h. The mixture was concentrated in vacuo and the residue was dissolved in H 2 O, then made alkaline to pH 9.5 with aq. NaOH. The resulting precipitate (7) 1H, dt, Jϭ7.7, 1.4 Hz), 7.04 (1H, dt, Jϭ7.7, 1.4 Aroyl-4-hydroxyphenyl) piperidine (8) (General Procedure F) An aroyl chloride (0.5 mol) was dropwise added to a stirred solution of 7 (0.45 mol), NaOH (21.6 g, 0.54 mol), isopropanol (240 ml), and H 2 O (240 ml) at 40°C over a 15 min period, then the mixture was stirred at 40°C for 1 h. A solution of MeOH (400 ml) and aq. NaOH (20% w/w) (59.7 g, 0.498 mol) was next added to the mixture, then stirred at 50°C for 1 h. After cooling, the mixture was acidified with aq. HCl to pH 4, and the resulting precipitate (8) was collected by filtration as a white solid.
Compounds 8 except 8aI and 8aK were synthesized according to general procedure F. Compound 8aI was synthesized from 7a according to the procedure for the synthesis of 13 and the compound 8aK was synthesized from 7a according to general procedure A. Modified Synthetic Procedure of 9aA NaOH (60.0 g, 2.50 mol) was added in small portions to a stirred solution of 8aA (30.0 g, 0.1 mol) in acetone (420 g, 7.23 mol) at room temperature over a 15 min period, and then stirred at 35°C for 30 min. CHCl 3 (53.9 g, 0.451 mol) was added dropwise to the stirred mixture in such a way as to maintain the reaction temperature at 35°C for 1 h. The entire mixture was stirred at 35°C for 1 h, and then concentrated in vacuo. The residue was dissolved in H 2 O, and the mixture was washed with CHCl 3 and acidified with dilute HCl to pH 3. The resulting precipitate was collected by filtration and dissolved in CHCl 3 . The CHCl 3 solution was extracted with aq. Na 2 CO 3 and the aqueous layer was acidified with dilute HCl to pH 3 again, and the resulting precipitate was collected by filtration and washed with H 2 O. The solid was recrystallized from toluene to give 9aA (29.4 g, 76%) as a white solid. 2-[3-[1-(4-Fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4 -yl]phenoxy]-2-methylpropanoic Acid (12) A solution of 11 (1.00 g, 2.43 mmol) in a mixture of 1 N NaOH (10 ml), MeOH (10 ml), and 1,4-dioxane (10 ml) was stirred at room temperature for 1 h. The mixture was acidified with dilute HCl to pH 3 and extracted with CHCl 3 . The CHCl 3 layer was washed with H 2 O, dried, and concentrated in vacuo to give an oil which was crystallized from Et 2 O to give 12 (820 mg, 88%) as a white solid.
HR-MS
m/z: 299.1335 (Calcd for C 18 H 18 FNO 2 : 299.1322). IR n (KBr)
1-(4-Fluorobenzoyl)-4-(3-methoxyphenyl)piperazine (13)
A solution of 4-fluorobenzoyl chloride (1.80 g, 11.4 mmol) in THF (20 ml) was dropwise added to a stirred solution of 1-(3-methoxyphenyl)piperazine (2.0 g, 10.2 mmol) and Et 3 N (3.0 ml, 21.6 mmol) in THF (40 ml) at 0°C over a 15 min period, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated in vacuo, and the residue was dissolved in CHCl 3 1-(4-Fluorobenzoyl)-4-(3-hydroxyphenyl)piperazine (14) AlCl 3 (4.0 g, 29.9 mmol) was added in small portions to a stirred solution of 13 (3.14 g, 10.0 mmol) and ethanethiol (4.0 ml, 53.5 mmol) in CH 2 Cl 2 (120 ml) at 0°C over a 5 min period, and the mixture was stirred at room temperature for 8 h and concentrated in vacuo. The residue was dissolved in H 2 O, and the aqueous mixture was extracted with CHCl 3 -MeOH (15 : 1). The organic layer was washed with H 2 O, dried, and concentrated in vacuo to give an oil which was purified by column chromatography on silica gel, eluting with 3% MeOH in CHCl 3 to give 14 (2.10 g, 70%) as a white solid. mp 134-135°C. Animals Male ICR mice and male SD rats were obtained from Charles River Japan, Inc. (Tokyo, Japan). Male KK-A y mice were also obtained from CLEA Japan Inc. (Tokyo, Japan).
Chemicals Bezafibrate, fenofibrate, and gemfibrozil were purchased from Sigma (St. Louis, U.S.A.). For oral administration, the compounds were suspended in a vehicle (0.5% carboxymethylcellulose sodium solution containing 0.05% Tween 80). For the admixture in diet, normal-chow diet (MF; Oriental Yeast Co., Ltd., Tokyo, Japan), high-cholesterol diet (MF supplemented with 1.5% cholesterol and 0.5% cholic acid) and high-cholesterol diets containing 0.001, 0.003, and 0.01% 9aA, and 0.01, 0.03, and 0.1% bezafibrate were prepared (Oriental Yeast Co., Ltd., Tokyo, Japan). Serum T-CHOL, TG, b-LP, and glucose levels were measured with commercially available kits (Wako Chemicals Japan).
Hypolipidemic Activities in Normal or Hypercholesterolemic Mice
In the case of normal mice, drugs were orally administered to male ICR mice (7-weeks old, nϭ5) for 3 d. In the case of hypercholesterolemic mice, the high-cholesterol diet (1% cholesterol and 0.5% cholic acid) was given to male ICR mice (7-weeks old, nϭ6) for 7 d, and drugs were orally administered on days 6 and 7. The T-CHOL, b-LP, and TG levels in the serum were measured.
Hypolipidemic Effect in Hypecholesterolemic Rats
Male SD rats (7 weeks old, nϭ5) were given the high-cholesterol diet (1.5% cholesterol and 0.5% cholic acid) or high-cholesterol diet containing drugs for 2 weeks. The T-CHOL and TG levels in serum were measured.
Hypolipidemic Effect in Fructose-Induced Hypertriglyceridemic Rats Male SD rats (6 weeks old) were given 25% fructose in drinking water during the experimental period. After 12 d, rats were divided into the control and treatement groups (nϭ8), and were orally administered with 9aA, bezafibrate, fenofibrate, and gemfibrozil for 7 d. Twenty-four hours after the final administration, the serum TG levels were measured.
Hypoglycemic Effect in KK-A y mice Male KK-A y mice (13 weeks old, nϭ8) were administered 9aA (0.003%, 0.01%, and 0.03%) and bezafibrate (0.03%, 0.1%, and 0.3%) admixture in their diets for 2 weeks. The serum glucose and TG levels were measured.
Statistical Analysis Data were expressed as meanϮS.E. A statistical analysis of difference between the groups was performed with Dunnett's multiple comparison test followed by Bartlett's test. A Student's t-test or Aspin-Welch t-test were also used for comparison between the two groups. A p-value level less than 0.05 (2-side) was considered as statistically significant.
